Kristine Peterson

Valeritas, Inc. engages in the development and commercialization of drug delivery solutions for the treatment of diabetes. Its product, V-Go wearable insulin delivery device, which enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery by using one type of insulin at a continuous preset basal rate over a 24-hour period and provides on-demand bolus dosing for meals and snacks. The company was founded on August 2, 2006 and is headquartered in Bridgewater, NJ.

Biovail Pharmaceuticals, Inc. researches and develops pharmaceutical medicines. The company products include Wellbutrin SR, Retavase, Zyban and Tiazac XC in Canada and Zovirax Ointment and Zovirax Cream in the United States. The company is headquartered in Bridgewater, NJ.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Biovail Corp. develops and manufactures pharmaceutical products. The company provides different types of products which include Wellbutrin SR, Retavase, Zyban and Tiazac XC in Canada and Zovirax Ointment and Zovirax Cream in the United States. Its products are used for cardiovascular disease, central nervous system disorders, pain management and other niche areas. It was founded on March 29, 1994 and is headquartered in Mississauga, Canada.

Valeritas Holdings, Inc. develops and commercializes insulin delivery devices. The company was founded by Leisa Swanson and Robert R. Gonnelli on August 2, 2006 and is headquartered in Bridgewater, NJ.

Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal.

AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark.